Laniece Delaunay, CharlotteMelo, AryseMaurel, MarineMazagatos, ClaraGoerlitz, LuiseO'Donnell, JoanOroszi, BeatrixSève, NoémieRodrigues, Ana PaulaMartínez-Baz, IvánMeijer, AdamMlinarić, IvanLatorre-Margalef, NeusLazar, MihaelaPérez-Gimeno, GloriaDürrwald, RalfBennett, CharleneTúri, GergőRameix-Welti, Marie-AnneGuiomar, RaquelCastilla, JesúsHooiveld, MariëtteKurečić Filipović, SanjaSamuelsson Hagey, ToveDijkstra, FrederikaBorges, VítorRamos Marín, VioletaBacci, SabrinaKaczmarek, MarlenaKissling, EstherEuropean Primary Care Vaccine Effectiveness Group2024-11-112024-11-112024-07-25Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. Vaccine. 2024 Jul 25;42(19):3931-3937.0264-410Xhttps://hdl.handle.net/20.500.12105/25486Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)]. Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016/j.vaccine.2024.06.056. PMID: 38971666In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case-control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26-53 %) overall, 48 % (95 % CI: 31-61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3-49 %) at 6-14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19EuropeMulticentre studySARS-CoV-2Test-negative designVaccine effectivenessAdolescentAdultAgedCOVID-19 VaccinesCOVID-19Case-Control StudiesEuropeFemaleHumansImmunization ProgramsMaleMiddle AgedPrimary Health CareSARS-CoV-2VaccinationVaccine EfficacyYoung AdultAttribution-NonCommercial-NoDerivatives 4.0 International3883952142193931-393710.1016/j.vaccine.2024.05.0671873-2518Vaccineopen access